{"slideshow_credits": null, "snippet": "The companies making the narcotic painkillers OxyContin and Opana have introduced tamper-resistant pills, hoping to slow adoption of the drugs\u2019 generic versions.", "abstract": "Purdue Pharma and Endo Pharmaceuticals, makers of brand name pain-relief drugs OxyContin and Opana, introduce versions that are more resistant to tampering techniques abusers use to release the pills' narcotics; companies hope that move will convince regulators to delay generic versions of the drugs that are not tamper-resistant, arguing that older designs will feed street demand for strong painkillers.", "section_name": "Health", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}, {"firstname": "Barry", "role": "reported", "lastname": "MEIER", "rank": 2, "organization": ""}], "original": "By KATIE THOMAS and BARRY MEIER", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/01/02/health/drug-makers-losing-a-bid-to-foil-generic-painkillers.html", "lead_paragraph": "The companies making the narcotic painkillers OxyContin and Opana have introduced tamper-resistant pills, hoping to slow adoption of the drugs\u2019 generic versions.", "headline": {"main": "Drug Makers Losing a Bid to Foil Generic Painkillers", "print_headline": "Drug Makers Losing a Bid To Foil Generic Painkillers"}, "_id": "50e3876500315214fbb81fae", "word_count": "1043", "multimedia": [{"height": 199, "url": "images/2013/01/02/business/JP-PAIN/JP-PAIN-articleLarge.jpg", "legacy": {"xlarge": "images/2013/01/02/business/JP-PAIN/JP-PAIN-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "199"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/01/02/business/PAIN/PAIN-thumbStandard.jpg", "legacy": {"thumbnail": "images/2013/01/02/business/PAIN/PAIN-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2013-01-02T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "5"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Endo Pharmaceuticals Inc", "name": "organizations", "is_major": "Y", "rank": "8"}, {"value": "OxyContin (Drug)", "name": "subject", "is_major": "Y", "rank": "6"}, {"value": "Purdue Pharma", "name": "organizations", "is_major": "Y", "rank": "7"}, {"value": "Pain-Relieving Drugs", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Drug Abuse and Traffic", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Generic Brands and Products", "name": "subject", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}